



Metabolic Syndrome and NASH: From Molecular Basis to Therapy

Guest Editors:

Dr. Juan Manuel Pericas

Dr. Andreea Ciudin

Dr. Francisco Javier Cubero

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

The rising incidence of non-alcoholic fatty liver disease (NAFLD) globally goes hand in hand with the current epidemics of obesity. The relationship between body weight, fat accumulation and inflammation is probably the most relevant interaction within the constellation of metabolic syndrome leading to steatohepatitis (NASH), liver fibrosis, cirrhosis, cardiovascular complications and end-stage liver disease, namely, hepatocellular carcinoma. Therefore, much attention has been given to this special and complex link between body weight and the severity of NASH from the mechanistic and therapeutic perspectives, leading to a burgeoning and exciting field of research and drug development.

We invite investigators to contribute with either original research or review articles focusing on the variety of altered molecular mechanisms that link systemic inflammation, adipose tissue and liver fibrosis and their role in NASH and associated complications, as well as on the strategies for addressing the problem from a clinical and epidemiological perspective.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI